{"preliminary_commentary":{"by_channel":{"x_thread":11,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02335411\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["pembrolizumab"],["pembrolizumab","cisplatin","5-fluorouracil"],["pembrolizumab","cisplatin","capecitabine"]],"indication":"recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma","name":"KEYNOTE-059","nct_id":"NCT02335411","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keynote-059-nct02335411. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W)","label":"Cohort 1: Pembrolizumab monotherapy, previously treated","type":"EXPERIMENTAL"},{"description":"Participants receive pembrolizumab 200 mg IV each 3-week cycle (Q3W) + cisplatin 80 mg/m\\^2 IV Q3W for up to 6 cycles + 5-FU 800 mg/m\\^2 IV on Days 1-5 every 3 weeks or (Japan only) capecitabine 1000 mg/m\\^2 orally, twice per day (BID) on Days 1-14 of each 3-week cycle","label":"Cohort 2: Pembrolizumab combination therapy, treatment naive","type":"EXPERIMENTAL"},{"description":"Programmed death-ligand 1 (PD-L1) positive participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W)","label":"Cohort 3: Pembrolizumab monotherapy, treatment naive, PD-L1 positive","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2021-07-23","type":"ACTUAL"},"conditions":["Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma"],"enrollment":{"count":318,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"pembrolizumab","otherNames":["MK-3475"],"type":"BIOLOGICAL"},{"name":"cisplatin","otherNames":["PLATINOL®"],"type":"DRUG"},{"name":"5-FU","otherNames":["ADRUCIL®"],"type":"DRUG"},{"name":"capecitabine","otherNames":["XELODA®"],"type":"DRUG"}],"last_update":"2022-08-08","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil in Subjects With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-059)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-07-23","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants Experiencing Adverse Events (AEs)","timeFrame":"Up to approximately 65 months"},{"measure":"Number of Participants Discontinuing Study Drug Due to AEs","timeFrame":"Up to approximately 52 months"},{"measure":"Objective Response Rate (ORR) For All Participants in Cohorts 1 and 3","timeFrame":"Up to approximately 75 months"},{"measure":"Objective Response Rate For PD-L1 Positive Participants in Cohorts 1 and 3","timeFrame":"Up to approximately 75 months"}],"references":[{"citation":"Janjigian YY, Cecchini M, Shitara K, Enzinger PC, Wainberg ZA, Chau I, Satoh T, Lee J, Nebozhyn M, Loboda A, Kobie J, Vajdi A, Shih CS, Cristescu R, Cao ZA. Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies. JCO Precis Oncol. 2025 Mar;9:e2400456. doi: 10.1200/PO-24-00456. Epub 2025 Mar 21.","pmid":"40117530","type":"DERIVED"},{"citation":"Topp BG, Channavazzala M, Mayawala K, De Alwis DP, Rubin E, Snyder A, Wolchok JD, Ribas A. Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression. Cancer Cell. 2023 Sep 11;41(9):1680-1688.e2. doi: 10.1016/j.ccell.2023.08.004.","pmid":"37699333","type":"DERIVED"},{"citation":"Muro K, Shitara K, Yamaguchi K, Yoshikawa T, Satake H, Hara H, Sugimoto N, Machida N, Goto M, Kawakami H, Amagai K, Omuro Y, Esaki T, Hironaka S, Nishina T, Komatsu Y, Matsubara H, Shiratori S, Han S, Satoh T, Ohtsu A. Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer. J Gastrointest Cancer. 2023 Sep;54(3):951-961. doi: 10.1007/s12029-023-00920-9. Epub 2023 Apr 10.","pmid":"37037952","type":"DERIVED"},{"citation":"Cristescu R, Aurora-Garg D, Albright A, Xu L, Liu XQ, Loboda A, Lang L, Jin F, Rubin EH, Snyder A, Lunceford J. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer. 2022 Jan;10(1):e003091. doi: 10.1136/jitc-2021-003091.","pmid":"35101941","type":"DERIVED"},{"citation":"Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, Bang YJ, De Vita F, Landers G, Yen CJ, Chau I, Elme A, Lee J, Ozguroglu M, Catenacci D, Yoon HH, Chen E, Adelberg D, Shih CS, Shah S, Bhagia P, Wainberg ZA. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol. 2021 Jun 1;7(6):895-902. doi: 10.1001/jamaoncol.2021.0275.","pmid":"33792646","type":"DERIVED"},{"citation":"Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 2019 Jul;22(4):828-837. doi: 10.1007/s10120-018-00909-5. Epub 2019 Mar 25.","pmid":"30911859","type":"DERIVED"},{"citation":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013. Epub 2018 May 10.","pmid":"29543932","type":"DERIVED"}],"start_date":{"date":"2015-02-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)","url":"https://clinicaltrials.gov/study/NCT02335411"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keynote-059-nct02335411"}